Panelists discuss how real-world analyses of chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory multiple myeloma (R/R MM), as presented in abstract #2408 by Amoozgar et al at ASH 2024, provide insights into the comparative efficacy and safety of ciltacabtagene autoleucel and idecabtagene vicleucel, highlighting differences between real-world outcomes and clinical trial results.
1 week Ago Video content above is prompted by the following: CAR T-Cell Therapies in R/R Multiple Myeloma: Real-World Insights Key Findings Comparative Performance Potential Implications Limitations and Considerations Clinical Relevance.
